Business
Marvel Biosciences Appoints Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - November 9, 2021) - Marvel Biosciences Corp. (TSXV: MRVL)...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences Appoints Scientific Advisory BoardCalgary, Alberta--(Newsfile Corp. - November 9, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce the creation of its scientific advisory board to help guide the development of its lead asset, MB-204, a fluorinated derivative of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world, whose consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. \"I am pleased to welcome all the members of the scientific advisory board to help guide the development of our lead compound MB-204 for neurological and non-neurological diseases,\" stated Mark Williams, President and Chief Science Officer of Marvel Biosciences. \"Our preclinical studies have shown promising results in terms of efficacy and safety, and as we move toward clinical testing with our lead asset, a strong scientific advisory board will be critical to our success.\"The scientific advisory board members include:Dr. David Blum adds crucial depth to the scientific board for his highly relevant research in the A2A receptor antagonists in cognition, brain lesions, and tau pathology for applications in Alzheimer's Disease (AD). Dr. Blum is a Senior Investigator and a Research Director of the Alzheimer & Tauopathies team at Lille Neuroscience & Cognition Inserm center in Lille. Dr. Blum is an expert in neuropathological studies on Tau (and its link to metabolism & neuroinflammation) and purine (and the role of purinergic signalling in neurodegeneration). One of Dr. Blum's current projects is to provide novel insights into the impact of neuro-glial A2A signalling on cognition and brain lesions in transgenic AD models. This work emphasizes that A2A receptor dysfunction is instrumentally involved in the loss of neuronal synapses driven by Tau pathology in AD and Tauopathies.Dr. Jared Young, Ph.D., is a Professor in the Department of Psychiatry at the University of California San Diego and brings significant expertise to the scientific board as a leader in translational models to ...